

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/094476 A3

(51) International Patent Classification⁷: **C07K 16/44**,
14/47, G01N 33/53, A61P 35/00, C12N 15/12, 15/63,
15/09, A61K 31/7088, C07K 19/00, 16/46, A61K 39/395,
G01N 33/574

(21) International Application Number:
PCT/US2004/011793

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/463,656 16 April 2003 (16.04.2003) US

(71) Applicant (for all designated States except US): **GENEN-
TECH, INC.** [US/US]; 1 DNA Way, South San Francisco,
CA 94080-4990 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ACKERLY, Heidi**
[US/US]; Box 333, Star Route 2, La Honda, CA 94020
(US). **ASHKENAZI, Avi** [US/US]; 1456 Tarrytown
Street, San Mateo, CA 94402 (US). **EBERHARD, David**
[US/US]; #212, 360 Guerrero Street, San Francisco, CA
94103 (US). **FRANTZ, Gretchen** [US/US]; 135 San
Benito Way, San Francisco, CA 94127 (US). **FRENCH,
Dorothy** [US/US]; 318 Beacon Shores Drive, Redwood
City, CA 94065 (US). **FUH, Germaine** [US/US]; 149
Amapola Avenue, Pacifica, CA 94044 (US). **HONGO,
Jo-Anne** [US/US]; 31 Shaw Court, Redwood City, CA
94061 (US). **LEE, Chingwei** [CN/US]; Apt. 102, 165
Buckingham Way, San Francisco, CA 94132 (US).
MARSTERS, Scot [US/US]; 990 Cherry Street, San
Carlos, CA 94070 (US). **PITTI, Robert** [US/US]; 1110
Liberty Street, El Cerrito, CA 94530 (US). **RAAB, Helga**

[DE/US]; 715 Shields Street, San Francisco, CA 94132
(US). **SOROCEANU, Liliana** [RO/US]; Apt. 6, 3042
Sacramento Street, San Francisco, CA 94115 (US). **VAR-
FOLOMEEV, Evgeny** [RU/US]; 7102 Shelter Creek
Lane, San Bruno, CA 94066 (US). **WOLF, Beni** [US/US];
607 Seasons Lane, Redwood City, CA 94065 (US).

(74) Agents: **SHIN, Elinor et al.**; MS 49, 1 DNA Way, South
San Francisco, CA 94080-4990 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
16 June 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS RELATING TO STOP-1

(57) Abstract: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.



WO 2004/094476 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/011793

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/44 C07K14/47 G01N33/53 A61P35/00 C12N15/12
C12N15/63 C12N15/09 A61K31/7088 C07K19/00 C07K16/46
A61K39/395 G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, MEDLINE, BIOSIS, CHEM ABS Data, WPI Data, PAJ, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

X	<p>EP 1 179 540 A (TAKEDA CHEMICAL INDUSTRIES LTD) 13 February 2002 (2002-02-13) cited in the application</p> <p>example 7 claims 1-8 SEQ ID No. 2</p> <p style="text-align: center;">----- -/-</p>	<p>1, 17-22, 27-29, 34, 36-38, 40-43</p>
---	---	--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 November 2004

Date of mailing of the international search report

1 1. 03. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ulbrecht, M

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2004/011793

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - ☒ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material
 - ☒ in written format
 - ☒ in computer readable form
 - c. time of filing/furnishing
 - ☐ contained in the international application as filed
 - ☐ filed together with the international application in computer readable form
 - ☒ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/011793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/16602 A (GODDARD AUDREY ; WILLIAMS P MICKEY (US); GENENTECH INC (US); WU THOMAS) 28 February 2002 (2002-02-28) cited in the application page 7, line 15 - page 17, line 15 figure 7 SEQ ID No. 7	1,17-22, 27-29, 34, 41-43, 47,49, 52,54,61
Y		36-38, 40,48, 50,53
X	----- WO 02/071928 A (GANNAVARAPU MANJULA ; HOERSCH SEBASTIAN (US); GLATT KAREN (US); SEN AM) 19 September 2002 (2002-09-19) page 39, paragraph 2 page 50, paragraph 2 - page 64, paragraph 2 page 72, paragraph 3 - page 95, paragraph 3 claim 1 tables 1,2	1,17-22, 27-29, 34, 41-43, 47,49, 52,54,61
Y		36-38, 40,48, 50,53
X	----- WO 92/09690 A (GENENTECH INC) 11 June 1992 (1992-06-11) example 11 figures 10,11 claim 46	12,13, 17-22, 27-29, 41-43
Y	----- WO 00/73346 A (US HEALTH ; PASTAN IRA (US); CHOWDHURY PARTHA S (US)) 7 December 2000 (2000-12-07) page 8, column 23 - column 29 page 40, column 24 - page 45, column 28	36-38, 40,48, 50,53
A	----- US 5 821 337 A (CARTER PAUL J ET AL) 13 October 1998 (1998-10-13) cited in the application the whole document ----- -/--	1-22, 27-31, 33,34, 36-38, 40-43, 47-54, 61-63,67

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/011793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>HOLT L J ET AL: "Domain antibodies: proteins for therapy" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, November 2003 (2003-11), pages 484-490, XP004467495 ISSN: 0167-7799 the whole document -----</p>	5-11

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US2004/011793

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1179540	A	13-02-2002	AU 4778600 A	12-12-2000
			CA 2374341 A1	30-11-2000
			EP 1179540 A1	13-02-2002
			WO 0071581 A1	30-11-2000
			JP 2001029090 A	06-02-2001
WO 0216602	A	28-02-2002	AU 2055401 A	12-06-2001
			AU 2590901 A	03-07-2001
			AU 3434601 A	12-06-2001
			AU 5516801 A	17-09-2001
			AU 6531101 A	17-12-2001
			AU 6802801 A	24-09-2001
			AU 6810801 A	04-03-2002
			AU 7011801 A	04-03-2002
			AU 7197301 A	05-02-2002
			AU 7315001 A	30-01-2002
			AU 7573000 A	26-03-2001
			AU 7885201 A	08-01-2002
			AU 8490601 A	04-03-2002
			AU 8678501 A	04-03-2002
			CA 2380355 A1	08-03-2001
			CA 2390786 A1	07-06-2001
			CA 2391374 A1	28-06-2001
			CA 2391455 A1	07-06-2001
			CA 2401448 A1	20-09-2001
			CA 2410162 A1	13-12-2001
			CA 2412211 A1	03-01-2002
			CA 2416456 A1	31-01-2002
			CA 2416538 A1	31-01-2002
			CA 2419541 A1	28-02-2002
			CA 2420140 A1	28-02-2002
			CA 2420176 A1	28-02-2002
			CA 2420193 A1	28-02-2002
			EP 1208202 A2	29-05-2002
			EP 1250426 A2	23-10-2002
			EP 1240325 A2	18-09-2002
			EP 1234036 A2	28-08-2002
			EP 1286749 A1	05-03-2003
			EP 1259614 A2	27-11-2002
			EP 1311679 A2	21-05-2003
			EP 1311674 A2	21-05-2003
			EP 1309685 A2	14-05-2003
			EP 1354040 A2	22-10-2003
			EP 1309620 A2	14-05-2003
			EP 1311662 A2	21-05-2003
			EP 1311668 A2	21-05-2003
			EP 1489095 A1	22-12-2004
			EP 1445317 A2	11-08-2004
			EP 1445318 A2	11-08-2004
			JP 2004507204 T	11-03-2004
			JP 2003530082 T	14-10-2003
			JP 2004522404 T	29-07-2004
			JP 2003527104 T	16-09-2003
			JP 2004508805 T	25-03-2004
			JP 2004510409 T	08-04-2004
			JP 2004506413 T	04-03-2004
WO 02071928	A	19-09-2002	WO 02071928 A2	19-09-2002

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US2004/011793

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02071928	A		US 2003087250 A1	08-05-2003
WO 9209690	A	11-06-1992	AT 164395 T	15-04-1998
			CA 2095633 A1	04-06-1992
			CA 2405246 A1	11-06-1992
			DE 69129154 D1	30-04-1998
			DE 69129154 T2	20-08-1998
			DK 564531 T3	28-09-1998
			EP 0564531 A1	13-10-1993
			ES 2113940 T3	16-05-1998
			GR 3026468 T3	30-06-1998
			JP 3267293 B2	18-03-2002
			JP 7503600 T	20-04-1995
			JP 2002119294 A	23-04-2002
			JP 2002136295 A	14-05-2002
			JP 2004121261 A	22-04-2004
			US 5750373 A	12-05-1998
			US 5534617 A	09-07-1996
			WO 9209690 A2	11-06-1992
			US 5688666 A	18-11-1997
			US 5780279 A	14-07-1998
			US 5846765 A	08-12-1998
			US 5821047 A	13-10-1998
			US 5834598 A	10-11-1998
			US 6022711 A	08-02-2000
			US 6143523 A	07-11-2000
			US 6040136 A	21-03-2000
WO 0073346	A	07-12-2000	AU 5303700 A	18-12-2000
			CA 2374398 A1	07-12-2000
			EP 1180123 A1	20-02-2002
			JP 2003502030 T	21-01-2003
			WO 0073346 A1	07-12-2000
US 5821337	A	13-10-1998	AU 5083193 A	15-03-1994
			WO 9404679 A1	03-03-1994
			US 6054297 A	25-04-2000
			AT 255131 T	15-12-2003
			AU 675916 B2	27-02-1997
			AU 2250992 A	12-01-1993
			CA 2103059 A1	15-12-1992
			CA 2481259 A1	23-12-1992
			DE 69233254 D1	08-01-2004
			DE 69233254 T2	16-09-2004
			DK 590058 T3	29-03-2004
			EP 1400536 A1	24-03-2004
			EP 0590058 A1	06-04-1994
			EP 0940468 A1	08-09-1999
			ES 2206447 T3	16-05-2004
			JP 6508267 T	22-09-1994
			JP 2005000169 A	06-01-2005
			LU 91067 A9	02-04-2004
			NL 300145 I1	01-06-2004
			WO 9222653 A1	23-12-1992
			US 6407213 B1	18-06-2002
			US 6719971 B1	13-04-2004
			US 6800738 B1	05-10-2004
			US 6639055 B1	28-10-2003

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/011793

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5821337	A	US 2004236078 A1	25-11-2004

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/011793

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 47-54, 61
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 30-33, 51, 63, 67 (all completely)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-22, 34, 37, 38, 47-50, 61 (all completely); 27-29, 36, 40-43, 52-54 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US2004 /011793

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 47-50 and 61 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 51-54 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.1

Claims Nos.: 47-54,61

Claims 47-50,61:

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

Claims 51-54:

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box II.2

Claims Nos.: 30-33,51,63, 67 (all completely)

Claims 30-33, 51, 63 and 67 relate to a STOP-1 antagonist and the use thereof, respectively. It cannot be determined which compounds fall under the definition of a STOP-1 antagonist. Although claims 30, 31 and 63 define the binding site of the said antagonist, the compound is not defined in structural terms. As the said antagonist is not defined, the subject-matter of the said claims is also not defined and a meaningful search of these claims insofar as they relate to said antagonist is not possible (Art. 6 PCT).

Moreover, claim 33 refers to a "stromal targeting agent" which is not clear, thereby further rendering a meaningful search of the scope of said claim impossible (Art. 6 PCT).

Consequently, claims 30-33, 51, 63 and 67 have not been searched.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US2004 /011793

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-22,34,37,38,47-50,61 (all completely); 27-29, 36, 40-43, 52-54 (all partially)

A monoclonal antibody (mAb) that specifically binds to an oligomeric form of human STOP-1; a mAb that specifically binds to amino acids 33-52 or 33-53 of human STOP-1; a mAb that specifically binds to amino acids 94-243 of human STOP-1; a mAb comprising the three amino acid sequences defined in any of claims 5, 9 and 10; a mAb comprising the amino acid sequence of the heavy chain of any of Fig. 27-31 or 34; a mAb having the biological characteristics of a mAb selected from S4, S7, S9, S16, F5 and 6B12; a mAb that specifically binds to STOP-1, wherein the binding of the mAb can be inhibited by a second mAb selected from S4, S7, S9, S16, F5 and 6B12; a mAb that specifically binds to STOP-1, wherein the mAb comprises the light and heavy chain sequences of any S4, S7, S9, S16, F5 and 6B12; a nucleic acid molecule encoding any of said mAbs; a vector comprising said nucleic acid molecule; a host cell comprising said nucleic acid molecule; a composition comprising one of said mAbs; a composition comprising the said nucleic acid molecule; a method for producing any of said mAbs using the said nucleic acid; a method for diagnosing or monitoring a tumour of a patient; a method of inhibiting the growth of a tumour that overexpresses STOP-1 comprising administering to a patient the said mAb composition; a method for determining the presence of a STOP-1 polypeptide in a sample

2. claims: 23, 24, 55-57 (all completely); 27-29, 35, 36, 39-43, 52-54, 62 (all partially)

A STOP-1 polypeptide variant comprising a STOP-1 polypeptide that cannot be secreted; a nucleic acid encoding the said polypeptide; a vector comprising the said nucleic acid; a host cell comprising the said nucleic acid; a composition comprising said polypeptide; a composition comprising said nucleic acid; a method of producing a STOP-1 polypeptide using the said nucleic acid; a method of inhibiting the growth of a tumour that overexpresses STOP-1 comprising administering to a patient the said composition; a method of inhibiting the growth of a cell that overexpresses STOP-1 comprising the step of inhibiting the secretion of STOP-1 from the cell; an article of manufacture comprising a modified STOP-1 polypeptide or a STOP-1 polypeptide variant

3. claims: 25, 26, 58 (all completely); 27-29, 35, 36, 39-43, 52-54, 62 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A STOP-1 polypeptide variant that cannot disulfide bind with another STOP-1; a nucleic acid encoding the said polypeptide; a vector comprising the said nucleic acid; a host cell comprising the said nucleic acid; a composition comprising said polypeptide; a composition comprising said nucleic acid; a method of producing a STOP-1 polypeptide using the said nucleic acid; a method for preventing disulfide binding between STOP-1 molecules; a method of inhibiting the growth of a tumour that overexpresses STOP-1 comprising administering to a patient the said composition; an article of manufacture comprising a modified STOP-1 polypeptide or a STOP-1 polypeptide variant

4. claims: 44-46 (all completely)

A method for producing a STOP-1 polypeptide using a mammalian cell that is deficient in proteoglycan synthesis

5. claims: 59, 60 (all completely)

A method for cleaving STOP-1 comprising the step of incubating STOP-1 with a protease

6. claims: 64-66 (all completely)

A method of inducing cell migration in vitro comprising the administration of a STOP-1 polypeptide; a method of testing the activity of a candidate antagonist or agonist of STOP-1 on cell migration

7. claims: 68-82 (all completely)

A composition comprising an immunoadhesin that comprises a STOP-1 polypeptide and an Fc portion of an antibody; a composition comprising a molecule that potentiates the binding of a STOP-1 polypeptide to a cell surface; an article of manufacture comprising said STOP-1 potentiator or said immunoadhesin; a method of inducing angiogenesis using said STOP-1 potentiator or said immunoadhesin; a method for evaluating/identifying compounds affecting the binding of STOP-1 to cells.
